Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Cash from Financing Activities (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Cash from Financing Activities for 2 consecutive years, with $14.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 13242.71% to $14.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.5 million for FY2025, 89.88% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $14.7 million at Neuphoria Therapeutics, up from $3.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $14.7 million in Q4 2025, with the low at -$227338.0 in Q3 2024.